ClinicalTrials.gg
CompletedNCT03518801CBD-PEUpdated Nov 17, 2026Results posted

Cannabidiol and Prolonged Exposure

A Phase 2 interventional study of Prolonged Exposure and Cannabidiol in PTSD, sponsored by VA Office of Research and Development. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by VA Office of Research and Development · Phase 2, Interventional, and Treatment

How we know

Updated Nov 17, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
144
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 263 studies in Stress Disorders, Post-Traumatic by VA Office of Research and Development — 56 open to participants now, 65 under way, 4 of them phase 3. Stress Disorders, Post-Traumatic · VA Office of Research and Development.

Enrollment
72nd of 246
144 · median 87
Started
2019
with 24 others
Phase 2
23 of 263
5 open now
Registered
124th of 263
by date

Among the 263 studies in Stress Disorders, Post-Traumatic by VA Office of Research and Development, this one is the 72nd largest by enrollment of the 246 interventional ones that give a count, is one of 25 that started in 2019, is one of 23 in phase 2, and was the 124th registered.

Stress Disorders, Post-Traumatic

2,689 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

56 of the 263 studies in Stress Disorders, Post-Traumatic by VA Office of Research and Development are open now, in 1 country. Recruiting first, the newest first:

51 more — sign in →

By country, each count listing its studies:

All 56 open studies →

Where they have run

Who these studies take

Of the 416 Stress Disorders, Post-Traumatic studies recruiting now, 188 (45%) set no upper age limit and 202 (49%) stop at 75 or younger; 62 take children under 18; 88 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 263 studies in Stress Disorders, Post-Traumatic by VA Office of Research and Development, or all of them as a file.
02

Study summary

The trial will include a randomized control trial to evaluate the efficacy of using Cannabidiol (CBD), a non-intoxicating cannabinoid, as an adjunctive to Prolonged Exposure therapy (PE). The trial will compare PE + CBD to PE + placebo in a sample of 136 military Veterans with PTSD at the VA San Diego Medical Center. The study represents the logical and innovative next step for augmenting existing treatments and developing novel pharmacotherapy for PTSD. Findings from the proposed RCT will inform clinical practice and policy by investigating whether administration of CBD in the context of PE therapy will improve treatment outcomes for military Veterans with PTSD.

Read the detailed description

Prolonged exposure therapy (PE) is among the most efficacious treatments for PTSD and is designated as a VA/DoD frontline treatment. However, PE does not always lead to clinically meaningful symptom reductions in Veterans with PTSD. Successful PE treatment relies on extinction learning, which is often impaired in patients with PTSD. Cannabidiol (CBD) is a non-intoxicating phytocannabinoid. Administration of specific phytocannabinoids, like CBD, increase extinction learning in patients with PTSD, and could increase the speed and effectiveness of PE therapy. CBD also modulates 5-HT1A, which may directly improve hyperarousal/insomnia symptoms, and improve engagement and retention in treatment. Given these findings, adjunctive administration of CBD+PE could improve response rates to PE and reduce the number of sessions of PE needed to reach clinically meaningful change. The proposed study is designed to test the efficacy of using CBD in conjunction with PE for the treatment of PTSD in US Military Veterans. A randomized, controlled, double-blind study will compare Veterans who receive PE+CBD to PE+placebo. Participants will include 136 male and female Veterans from all service eras with PTSD. The primary hypothesis is that PE+CBD will reduce PTSD symptoms to a greater degree than PE+placebo.

03

Conditions studied

  • PTSD

Keywords

  • cannabidiol
  • CBD
  • PTSD
  • Veterans
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Over the age of 18 at the time of screening.
  • Judged by the study physician to be in generally good health.
  • Meet clinical criteria for Posttraumatic Stress Disorder (PTSD) on the Clinician-Administered PTSD Scale for (CAPS-5).
  • Negative urine pregnancy test.

Exclusion criteria

Exclusion Criteria:

  • History of significant allergic condition, significant drug-related , or allergic reaction to cannabinoids.
  • Used cannabis, synthetic cannabinoid, cannabinoid analogue, or any CBD or THC-containing product within 30 days of eligibility screening.
  • Patient has had a change in psychopharmacotherapy regimen in the last 4 weeks, or has any plans to change regimen over the course of the study.
  • Patient is engaged in trauma-related psychotherapy for PTSD.
  • Current or past diagnosis of dissociative identity disorder, eating disorder with active purging, personality disorders, primary psychotic disorder, or bipolar affective disorder type 1.
  • Patient is currently prescribed medications with possible CBD-drug interactions.
  • History of actual suicide attempt in the last 5 years.
  • Unmanaged obstructive sleep apnea.
  • Positive drug screen for THC, barbiturates, amphetamines (if not prescribed), benzodiazepines, and/or opiates.
  • History of treatment for, or evidence of, moderate to severe alcohol or drug abuse within the past year or regular alcohol consumption exceeding recommended limits.
  • Lifetime history of Cannabis Use Disorder.
  • Pregnant or breastfeeding.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
144 participants (actual)

Study arms

  • Experimental
    Prolonged Exposure + Cannabidiol

    Psychotherapy plus active medication

    Behavioral: Prolonged Exposure · Drug: Cannabidiol

  • Active comparator
    Prolonged Exposure + Placebo

    Psychotherapy plus placebo medication

    Behavioral: Prolonged Exposure · Drug: placebo

Interventions

  • BehavioralProlonged Exposure

    psychotherapy

    Also known as: PE

  • active medication

    Also known as: CBD

  • Drugplacebo

    non-active medication

06

What researchers measure

Primary outcomes

  1. Clinician-Administered PTSD Scale DSM 5 (CAPS-5)

    Change in PTSD Symptoms will be assessed by change in Total Severity Score (summed severity ratings on items 1-20) on the Clinician-Administered PTSD Scale DSM 5 (CAPS-5); CAPS-5 Total Severity scores range from 0 to 80; Higher scores indicate higher severity.

    Time frame: Baseline, Post Treatment (16-weeks), 1-Month Follow-up (20-weeks), 3-Month Follow-up (28-weeks)

Secondary outcomes

  1. PTSD Checklist (PCL-5)

    Rate of PTSD symptom reduction will be assessed by comparing the time-to-event of clinical response to treatment. The time-to-event is defined by number of PE sessions completed before patient achieves a 10-point reduction from baseline in total (summed) PTSD Checklist scores (PCL-5). PCL-5 Total Scores range from 0 to 80; Higher scores indicate worse functioning.

    Time frame: Baseline, Weekly (up to 16-weeks)

07

Results

Posted Oct 28, 2026
Limitations and caveats
Beginning in March 2020, study procedures transitioned from in-person to remote delivery in response to the COVID-19 pandemic. Scheduled therapy, assessment, and medication-management visits continued remotely, and study medication was mailed to participants. The UKU Side Effect Rating Scale was discontinued following the transition. Drug testing, originally conducted at baseline, after PE Session 6, and post-treatment, was limited to baseline testing.

Participant flow

Participants were recruited for a randomized, double-blind clinical trial evaluating cannabidiol as an adjunct to prolonged exposure therapy for PTSD in Veterans.

Participant flow — Overall Study
MilestoneProlonged Exposure + CannabidiolProlonged Exposure + Placebo
Started5046
Completed2731
Not completed2315
Withdrew: Spouse died10
Withdrew: Lost to follow-up53
Withdrew: Withdrawal by subject1711
Withdrew: Declined to talk about trauma01

Outcome measures

PrimaryClinician-Administered PTSD Scale DSM 5 (CAPS-5)

Change in PTSD Symptoms will be assessed by change in Total Severity Score (summed severity ratings on items 1-20) on the Clinician-Administered PTSD Scale DSM 5 (CAPS-5); CAPS-5 Total Severity scores range from 0 to 80; Higher scores indicate higher severity.

Time frame:
Baseline, Post Treatment (16-weeks), 1-Month Follow-up (20-weeks), 3-Month Follow-up (28-weeks)
Reported as:
Mean · Score
Clinician-Administered PTSD Scale DSM 5 (CAPS-5)
ScoreProlonged Exposure + CannabidiolProlonged Exposure + Placebo
Baseline36.92 ± 8.9635.05 ± 8.63
Post Treatment (16 weeks)22.55 ± 14.8623.07 ± 11.88
1-Month Follow-up (20 weeks)22.86 ± 14.2521.48 ± 12.74
3-Month Follow-up (28 weeks)21.17 ± 14.6421.93 ± 14.15
SecondaryPTSD Checklist (PCL-5)

Rate of PTSD symptom reduction will be assessed by comparing the time-to-event of clinical response to treatment. The time-to-event is defined by number of PE sessions completed before patient achieves a 10-point reduction from baseline in total (summed) PTSD Checklist scores (PCL-5). PCL-5 Total Scores range from 0 to 80; Higher scores indicate worse functioning.

Time frame:
Baseline, Weekly (up to 16-weeks)
Reported as:
Median · PE sessions
PTSD Checklist (PCL-5)
PE sessionsProlonged Exposure + CannabidiolProlonged Exposure + Placebo
PTSD Checklist (PCL-5)5 (3 to 7)5 (3 to 5)

Adverse events

Collected over From initiation of study medication through Week 16.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Prolonged Exposure + Cannabidiol0/46 (0%)0/46 (0%)11/46 (23.9%)
Prolonged Exposure + Placebo0/45 (0%)0/45 (0%)15/45 (33.3%)
Most frequent other events
Most frequent other events
EventProlonged Exposure + CannabidiolProlonged Exposure + Placebo
FatigueGeneral disorders6/468/45
HeadacheNervous system disorders3/466/45
Dry mouthGastrointestinal disorders3/463/45
NauseaGastrointestinal disorders0/463/45
SomnolenceNervous system disorders3/462/45

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Prolonged Exposure + CannabidiolProlonged Exposure + PlaceboTotal
Mean40.32 ± 13.7645.54 ± 14.4142.82 ± 14.24
Sex: Female, Male
Sex: Female, Male(Participants)Prolonged Exposure + CannabidiolProlonged Exposure + PlaceboTotal
Female161430
Male343266
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Prolonged Exposure + CannabidiolProlonged Exposure + PlaceboTotal
American Indian or Alaska Native112
Asian235
Native Hawaiian or Other Pacific Islander213
Black or African American7613
White353368
More than one race000
Unknown or Not Reported325
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Prolonged Exposure + CannabidiolProlonged Exposure + PlaceboTotal
Hispanic or Latino141226
Not Hispanic or Latino323466
Unknown or Not Reported404
CAPS-5 Total Severity Score
CAPS-5 Total Severity Score(Score)Prolonged Exposure + CannabidiolProlonged Exposure + PlaceboTotal
Mean36.92 ± 8.9635.05 ± 8.6336.03 ± 8.81
08

Study locations

1 site
  • VA San Diego Healthcare System, San Diego, CA
    San Diego, California 92161-0002, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2019 to primary completion in Sep 2025, 71 months.

Results were first posted in Oct 2026, 1 year after primary completion.

Of 87 non-industry phase 2 interventional studies under Stress Disorders, Post-Traumatic, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 59. This study's 71 months is above that.

Counting every sponsor, half of 118 studies reached it within 38 months; a quarter within 23 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2018
First posted
May 8, 2018
StartActual
Oct 1, 2019
Primary completionActual
Sep 30, 2025
CompletionActual
Sep 30, 2025
Results first posted
Oct 28, 2026
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted, then revised
posted Oct 28, 2026 · revised Nov 17, 2026
Enrollment
136→144
Nov 17, 2026
Documents
Show all 2 updates
  1. Nov 17, 2026
    Posted results revised
    Enrollment 136→144
    + 1 other change: verification date
  2. Oct 28, 2026
    Results posted
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03518801
Responsible party
Sponsor
First posted
May 8, 2018
Start date
Oct 1, 2019
Primary completion
Sep 30, 2025
Completion
Sep 30, 2025
Results posted
Oct 28, 2026
Last update
Nov 17, 2026

Study contacts

Catherine R Ayers, PhD
principal investigator · VA San Diego Healthcare System, San Diego, CA
Brian Martis, MD
principal investigator · VA San Diego Healthcare System, San Diego, CA

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cannabidiol

Start the discussion